WRX606

WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M) . WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC50 = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50 = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent[1][2].

Product Specifications

CAS Number

[899937-47-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MTOR

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/wrx606.html

Purity

95.65

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(CN1C(N(CCCC(NCC2=CC=C3OCOC3=C2)=O)C(C4=C1C=CC=C4)=O)=O)NC5=CC(Cl)=CC=C5

Molecular Formula

C28H25ClN4O6

Molecular Weight

548.97

Precautions

H302, H315, H319, H335

References & Citations

[1]Shams R, et al., In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. J Med Chem. 2022 Jan 27;65 (2) :1329-1341.|[2]Li, S., et al., (2023) . MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation. European journal of medicinal chemistry, 260, 115781.